Bigbear Pharmaceutical·Medication Guide

• What is apalutamide

  Apalutamide is to treatprostate cancerthat has spread to other parts of the body (metastatic) and still responds to a medical or surgical treatment th···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 73

• What happens if I miss a dose

  Take the missed dose on the same day you remember it. Take your next dose at the regular time and stay on your once-daily schedule. Do not take two do···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 74

• What should I avoid while taking apalutamide

  Apalutamide can cause seizures. Avoid activities that could be dangerous if you have an unexpected seizure.【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 73

• What other drugs will affect apalutamide

  Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 72

• What Is Apalutamide Used For

  Apalutamide is an oral anti-androgen medication, mainly used to treat non-metastatic or metastatic castration-resistant prostate cancer. It delays tum···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 73

• FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

  FDA Approval AnnouncementFebruary 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 72

• FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitiv

  FDA Approval AnnouncementHORSHAM, Pa., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today th···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 74

• Sotorasib (Lumakras) Patient Guide: How It Works, Side Effects, and Dosing Tips

  KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 73

• Sotorasib (Lumakras) Explained: Uses, Effectiveness, and What to Expect

  Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 72

• Common Sotorasib Side Effects and How to Manage Them: A Patient’s Guide

  In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 71

• Sotorasib (Lumakras) Dosage Guide: How to Take It Safely for NSCLC and mCRC

  Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 73

• New Sabril (Vigabatrin) Pediatric Formulation Shows Promise for Infantile Spasms in 2026 Clinical Tr

  On June 13, 2024, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib fo···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 71

• Sabril for Infantile Spasms (West Syndrome): A Complete Guide for Parents

  On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 72

• Understanding the Sabril (Vigabatrin) Black Box Warning: Risk of Permanent Vision Loss

  Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 72

• Sabril Side Effects: What to Expect and When to Call Your Doctor Immediately

  Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 72